|
1
|
Sahin U, Karikó K and Türeci Ö: mRNA-based
therapeutics-developing a new class of drugs. Nat Rev Drug Discov.
13:759–780. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Liu T, Liang Y and Huang L: Development
and delivery systems of mRNA vaccines. Front Bioeng Biotechnol.
9(718753)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ramachandran S, Satapathy SR and Dutta T:
Delivery strategies for mRNA vaccines. Pharm Med. 36:11–20.
2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yen A, Cheng Y, Sylvestre M, Gustafson HH,
Puri S and Pun SH: Serum nuclease susceptibility of mRNA cargo in
condensed polyplexes. Mol Pharm. 15:2268–2276. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yan Y, Liu XY, Lu A, Wang XY, Jiang LX and
Wang JC: Non-viral vectors for RNA delivery. J Control Release.
342:241–279. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hou X, Zaks T, Langer R and Dong Y: Lipid
nanoparticles for mRNA delivery. Nat Rev Mater. 6:1078–1094.
2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Buschmann MD, Carrasco MJ, Alishetty S,
Paige M, Alameh MG and Weissman D: Nanomaterial delivery systems
for mRNA vaccines. Vaccines (Basel). 9(65)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tang M, Sagawa A, Inoue N, Torii S, Tomita
K and Hattori Y: Efficient mRNA delivery with mRNA lipoplexes
prepared using a modified ethanol injection method. Pharmaceutics.
15(1141)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gallinari P, Di Marco S, Jones P, Pallaoro
M and Steinkühler C: HDACs, histone deacetylation and gene
transcription: From molecular biology to cancer therapeutics. Cell
Res. 17:195–211. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sakajiri S, Kumagai T, Kawamata N, Saitoh
T, Said JW and Koeffler HP: Histone deacetylase inhibitors
profoundly decrease proliferation of human lymphoid cancer cell
lines. Exp Hematol. 33:53–61. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Deng Y, Cheng Q and He J: HDAC inhibitors:
Promising agents for leukemia treatment. Biochem Biophys Res
Commun. 680:61–72. 2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Duvic M: Histone deacetylase inhibitors
for cutaneous T-cell lymphoma. Dermatol Clin. 33:757–764.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ishiguro K and Sartorelli AC: Activation
of transiently transfected reporter genes in 3T3 Swiss cells by the
inducers of differentiation/apoptosis-dimethylsulfoxide,
hexamethylene bisacetamide and trichostatin A. Eur J Biochem.
271:2379–2390. 2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yamano T, Ura K, Morishita R, Nakajima H,
Monden M and Kaneda Y: Amplification of transgene expression in
vitro and in vivo using a novel inhibitor of histone deacetylase.
Mol Ther. 1:574–580. 2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hattori Y, Tamaki K, Sakasai S, Ozaki KI
and Onishi H: Effects of PEG anchors in pegylated siRNA lipoplexes
on in vitro gene-silencing effects and siRNA biodistribution in
mice. Mol Med Rep. 22:4183–4196. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Guide for the Care and Use of Laboratory
Animals: National Research Council (US). 8th Edition. The National
Academies Press, Washington, DC, 2011.
|
|
17
|
Di J, Du Z, Wu K, Jin S, Wang X, Li T and
Xu Y: Biodistribution and non-linear gene expression of mRNA LNPs
affected by delivery route and particle size. Pharm Res.
39:105–114. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kumagai T, Wakimoto N, Yin D, Gery S,
Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y and Koeffler HP:
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid
(vorinostat, SAHA) profoundly inhibits the growth of human
pancreatic cancer cells. Int J Cancer. 121:656–665. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Takai N, Kawamata N, Gui D, Said JW,
Miyakawa I and Koeffler HP: Human ovarian carcinoma cells: Histone
deacetylase inhibitors exhibit antiproliferative activity and
potently induce apoptosis. Cancer. 101:2760–2770. 2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Butler LM, Agus DB, Scher HI, Higgins B,
Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA and Richon
VM: Suberoylanilide hydroxamic acid, an inhibitor of histone
deacetylase, suppresses the growth of prostate cancer cells in
vitro and in vivo. Cancer Res. 60:5165–5170. 2000.PubMed/NCBI
|
|
21
|
Hrzenjak A, Moinfar F, Kremser ML,
Strohmeier B, Petru E, Zatloukal K and Denk H: Histone deacetylase
inhibitor vorinostat suppresses the growth of uterine sarcomas in
vitro and in vivo. Mol Cancer. 9(49)2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang H, Huang C, Zhao L, Zhang H, Yang JM,
Luo P, Zhan BX, Pan Q, Li J and Wang BL: Histone deacetylase
inhibitors regulate P-gp expression in colorectal cancer via
transcriptional activation and mRNA stabilization. Oncotarget.
7:49848–49858. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Eliyahu H, Servel N, Domb AJ and Barenholz
Y: Lipoplex-induced hemagglutination: Potential involvement in
intravenous gene delivery. Gene Ther. 9:850–858. 2002.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Simberg D, Weisman S, Talmon Y, Faerman A,
Shoshani T and Barenholz Y: The role of organ vascularization and
lipoplex-serum initial contact in intravenous murine lipofection. J
Biol Chem. 278:39858–39865. 2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hockly E, Richon VM, Woodman B, Smith DL,
Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, et
al: Suberoylanilide hydroxamic acid, a histone deacetylase
inhibitor, ameliorates motor deficits in a mouse model of
Huntington's disease. Proc Natl Acad Sci USA. 100:2041–2046.
2003.PubMed/NCBI View Article : Google Scholar
|
